Telix Pharmaceuticals Limited (TLX)
Market Cap | 3.21B |
Revenue (ttm) | 664.23M |
Net Income (ttm) | 10.84M |
Shares Out | 338.40M |
EPS (ttm) | 0.04 |
PE Ratio | 226.31 |
Forward PE | 29.85 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 139,488 |
Open | 9.54 |
Previous Close | 9.29 |
Day's Range | 9.49 - 9.72 |
52-Week Range | 8.93 - 30.36 |
Beta | 2.38 |
Analysts | Strong Buy |
Price Target | 21.33 (+121.27%) |
Earnings Date | n/a |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.33, which is an increase of 121.27% from the latest price.
News

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Telix Pharmaceuticals Limited (NASDAQ:TLX) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 12:00 PM EDT Company Participants Christian Behrenbruch - Co-Founder, MD, Group C...

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 cli...

Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Telix Pharmaceuticals Limited (NASDAQ:TLX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Christian Behrenbruch - Co-Founder, MD, Group CEO...

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman
SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- On August 28, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares fall about 16% after the...

Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable
Despite recent FDA rejections and a ~50% share price drop, I remain bullish on TLX, viewing setbacks as surmountable. Strong revenue performance and cash flow stability provide TLX with ample runway t...

Telix Gets Second FDA Rejection For Kidney Cancer Drug
On Thursday, Telix Pharmaceuticals Limited TLX received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zi...

US FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancer
The U.S. Food and Drug Administration has requested additional data from Telix Pharmaceuticals on its application for a diagnostic drug to detect a form of kidney cancer, the Australian cancer diagnos...

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
SAN FRANCISCO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after t...

Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare...

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceutical...

Telix Pharmaceuticals Limited (TLX) Q2 2025 Earnings Call Transcript
Telix Pharmaceuticals Limited (NASDAQ:TLX) Q2 2025 Earnings Conference Call August 20, 2025 7:30 PM ET Company Participants Christian P. Behrenbruch - Co-Founder, MD, Group CEO & Executive Director D...

Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violation...

Telix Pharmaceuticals Limited (TLPPF) H1 2025 Earnings Call Transcript
Telix Pharmaceuticals Limited (OTCPK:TLPPF) H1 2025 Earnings Conference Call August 20, 2025 7:30 PM ET Company Participants Christian P. Behrenbruch - Co-Founder, MD, Group CEO & Executive Director D...

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30...

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens Berman
SAN FRANCISCO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after t...

Telix H1 2025 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the...

Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry
TLX boasts a diverse pipeline and strong sales growth, especially with Illuccix and Gozellix, supporting my continued confidence in their theranostics approach. Financials remain robust, with year-ove...

Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational perfo...

Gozellix Receives Permanent HCPCS Code
MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA1 PET2 imaging agen...

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Foo...

Telix Precision Medicine Announces AlFluor Radiochemistry Platform
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radi...

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and t...

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) provides further details on the agenda for the Co...

Telix Pharmeceuticals: Imaging Biomarkers Paving The Way For Theranostics
Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix and promising therapeutic programs in development. TLX's key imaging projects ...

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein...